Lakefront Biotherapeutics NV (LKFT)

NASDAQ: LKFT · USD

$32.1

+0.26 (+0.8%)· Recorded snapshot

Market cap	2B
Revenue (ttm)	1.1B
Net income (ttm)	681.6M
EPS (ttm)	$10.1
Shares out	65.7M
P/E (trailing)	3.2x
Volume	253,066
Beta	0.06

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.1B
Net income (ttm): 681.6M
EPS (ttm): $10.1
P/E (trailing): 3.2x
Market cap: 2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/E3.2

P25 15.4P50 25.8P75 43.5

ROE20.1

P25 -113.8P50 -46.5P75 -0.9

ROIC87.1

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All LKFT indicators

Market & fundamental data

Available fields

217

Groups with data

Currency

EUR

Showing 217 of 217 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001421876
Company name	Lakefront Biotherapeutics NV
Country	Belgium
Country code	US
CUSIP number	36315X101
Earnings date	2026-11-11
Earnings time	amc
Employees	196
Employees change	-256
Employees growth	-56.64%
Enterprise value	$-458.8M
Exchange	NASDAQ
Financial currency	EUR
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1999
Industry	Biotechnology
Is primary listing	No
Is SPAC	No
ISIN number	US36315X1019
Last 10-K release date	2026-03-26
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2B
Market cap category	Mid-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$32.08
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	LKFT
Website	https://lakefrontbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (3Y)	8.5x
Earnings yield	31.43%
FCF / EV yield	54.26%
FCF yield	-12.81%
Forward P/S	11.16x
Graham number	120.51402
Graham upside	275.67%
P/B ratio	0.54x
P/E ratio	3.18x
P/S ratio	1.78x
Price / tangible book value	0.7x
Price/EBITDA ratio	3.1x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	57.49%
EBITDA margin	57.43%
Gross margin	67.61%
Operating margin	57.49%
Pretax margin	58.31%
Profit margin	60.23%
Profit per employee	$3.5M
Profitable quarters	2
Profitable years	3
Revenue per employee	$5.8M
ROA	9.93%
ROA (5Y)	0.27%
ROCE	17.36%
ROE	20.12%
ROE (5Y)	0.58%
ROIC	87.08%
SBC / revenue	1.83%
Tax / revenue	-1.69%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (QoQ)	-85.49%
EPS growth quarters	2
EPS growth years	1
Gross profit growth 5Y	144.98%
Net income growth (QoQ)	-85.45%
Net income growth quarters	2
Net income growth years	1
Revenue growth	259.41%
Revenue growth (Q)	-81.45%
Revenue growth (QoQ)	86.85%
Revenue growth 10Y	29.9%
Revenue growth 3Y	125.91%
Revenue growth 5Y	13.01%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-5.1M
Depreciation and amortization	$-647,195
EBIT	$650.6M
EBITDA	$650M
EPS	$10.08
FCF per share	$-3.93
Financing cash flow	$-7M
Free cash flow	$-257.9M
Free cash flow minus SBC	$-278.1M
Gross profit	$765.2M
Income taxes	$-19.1M
Investing cash flow	$333.9M
Net borrowing	$-3.6M
Net cash flow	$73.4M
Net income	$681.6M
Operating cash flow minus SBC	$-272.9M
Operating income	$650.6M
Revenue	$1.1B
Stock-based compensation	$20.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	13.92
Book value per share	$56.79
Debt / EBITDA	0.01
Debt / equity	0
Interest coverage	664.53
Long-term assets	$1.3B
Long-term liabilities	$21.7M
Net cash (debt)	$2.6B
Net cash / market cap	126.75%
Net cash growth	-27.57%
Net debt / EBITDA	-3.93
Net debt / equity	-0.68
Piotroski F-Score	5
Property, plant and equipment	$85.6M
Shareholders' equity	$3.7B
Tangible book value	$2.9B
Tangible book value per share	$43.73
Total assets	$3.8B
Total cash	$2.6B
Total debt	$7.3M
Total liabilities	$100M
WACC	4.59%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.28
Current assets	$2.6B
Current liabilities	$78.3M
Current ratio	32.84
Inventory turnover	15.16
Net working capital	$1.2M
Quick ratio	32.65
Working capital	$2.6B
Working capital turnover	0.44

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.05%
Dividend yield	0%
Shareholder yield	-0.05%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-48.82%
10Y return CAGR	-6.48%
10Y total return	-48.82%
150-day SMA	$28.77
15Y price change	273.02%
15Y return CAGR	9.17%
15Y total return	273.02%
1D price change	0.82%
1M price change	9.19%
1M total return	9.19%
1W price change	4.91%
1W total return	4.91%
1Y price change	3.33%
1Y return CAGR	3.34%
1Y total return	3.33%
20-day SMA	$30.20
200-day SMA	$29.94
3M price change	14.04%
3M total return	14.04%
3Y price change	0.66%
3Y return CAGR	0.22%
3Y total return	0.66%
50-day SMA	$29.35
50-day SMA vs 200-day SMA	50under200
52-week high	$36.24
52-week high date	2026-02-24
52-week low	$25.68
52-week low date	2026-08-06
5Y price change	-37.96%
5Y return CAGR	-9.11%
5Y total return	-37.96%
6M price change	12.68%
6M total return	12.68%
All-time high	$274.03
All-time high date	2020-02-21
All-time low	$4.21
All-time low date	2008-12-12
Average true range (ATR)	$0.75
Average volume	273.5K
Beta (5Y)	0.06
Change from 52-week high	-11.48%
Change from 52-week low	24.92%
Change from all-time high	-88.29%
Change from all-time low	661.63%
Change from open	1.36%
Day's gap	-0.53%
Dollar volume	$8.1M
High price	$32.21
Low price	$31.55
Monthly RSI	50.86
Open price	$31.65
Position in 52-week range	80.3%
Premarket change	-0.35%
Premarket close	$31.82
Premarket price	$31.71
Previous close	$31.82
Price vs 150-day SMA	11.51%
Price vs 20-day SMA	6.24%
Price vs 200-day SMA	7.17%
Price vs 50-day SMA	9.3%
Relative volume	0.94
RSI	69.02
Sharpe ratio	0.11
Sharpe ratio (3Y)	-0.05
Sharpe ratio (5Y)	-0.26
Sortino ratio	0.38
Sortino ratio (3Y)	0.11
Sortino ratio (5Y)	-0.2
Volume	253.1K
Weekly RSI	62.57
YTD price change	-1.9%
YTD total return	-1.9%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	22.5M
Float percentage	34.29%
Shares change (QoQ)	0.25%
Shares change (YoY)	0.05%
Shares held by insiders	0.01%
Shares held by institutions	32.24%
Shares outstanding	65.7M
Short % of shares	8.28%
Short ratio	10.6 days

Deeper analysis on LKFT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this LKFT report

Is a complete LKFT research report available?

No complete published report is available for Lakefront Biotherapeutics NV (LKFT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Lakefront Biotherapeutics NV (LKFT)

Price

Financial snapshot

Fair-value bridge

Latest news · LKFT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All LKFT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on LKFT

Frequently asked questions